329 related articles for article (PubMed ID: 18088233)
21. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
[TBL] [Abstract][Full Text] [Related]
22. How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer.
Couto JP; Prazeres H; Castro P; Lima J; Máximo V; Soares P; Sobrinho-Simões M
J Clin Pathol; 2009 May; 62(5):414-21. PubMed ID: 19147628
[TBL] [Abstract][Full Text] [Related]
23. BRAF mutation in thyroid cancer.
Xing M
Endocr Relat Cancer; 2005 Jun; 12(2):245-62. PubMed ID: 15947100
[TBL] [Abstract][Full Text] [Related]
24. Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and review of the literature.
Rossi S; Fugazzola L; De Pasquale L; Braidotti P; Cirello V; Beck-Peccoz P; Bosari S; Bastagli A
Endocr Relat Cancer; 2005 Jun; 12(2):281-9. PubMed ID: 15947103
[TBL] [Abstract][Full Text] [Related]
25. Thyroid carcinoma: molecular pathways and therapeutic targets.
Nikiforov YE
Mod Pathol; 2008 May; 21 Suppl 2(Suppl 2):S37-43. PubMed ID: 18437172
[TBL] [Abstract][Full Text] [Related]
26. B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas.
Trovisco V; Soares P; Sobrinho-Simões M
Hum Pathol; 2006 Jul; 37(7):781-6. PubMed ID: 16784975
[TBL] [Abstract][Full Text] [Related]
27. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
Zuo H; Nakamura Y; Yasuoka H; Zhang P; Nakamura M; Mori I; Miyauchi A; Kakudo K
Pathol Int; 2007 Jan; 57(1):12-20. PubMed ID: 17199737
[TBL] [Abstract][Full Text] [Related]
28. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
29. Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement: relationship with clinico-pathological features.
Durand S; Ferraro-Peyret C; Joufre M; Chave A; Borson-Chazot F; Selmi-Ruby S; Rousset B
Endocr Relat Cancer; 2009 Jun; 16(2):467-81. PubMed ID: 19208736
[TBL] [Abstract][Full Text] [Related]
30. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
31. BRAF in papillary thyroid carcinoma of ovary (struma ovarii).
Schmidt J; Derr V; Heinrich MC; Crum CP; Fletcher JA; Corless CL; Nosé V
Am J Surg Pathol; 2007 Sep; 31(9):1337-43. PubMed ID: 17721188
[TBL] [Abstract][Full Text] [Related]
32. [Intracellular signaling mechanisms in thyroid cancer].
Mondragón-Terán P; López-Hernández LB; Gutiérrez-Salinas J; Suárez-Cuenca JA; Luna-Ceballos RI; Erazo Valle-Solís A
Cir Cir; 2016; 84(5):434-43. PubMed ID: 27423883
[TBL] [Abstract][Full Text] [Related]
33. Molecular diagnostics of thyroid tumors.
Nikiforov YE
Arch Pathol Lab Med; 2011 May; 135(5):569-77. PubMed ID: 21526955
[TBL] [Abstract][Full Text] [Related]
34. [Frequency of RET/PTC rearrangement and somatic BRAF mutation in papillary thyroid cancer].
Rumiantsev PO; Zaletaev DV; Vasil'ev EV; Saenko VA; Il'in AA; Rumiantseva UV; Abrosimov AIu; Medvedev VS
Vopr Onkol; 2006; 52(2):145-9. PubMed ID: 17195637
[TBL] [Abstract][Full Text] [Related]
35. Reduction of false-negative papillary thyroid carcinomas by the routine analysis of BRAF(T1799A) mutation on fine-needle aspiration biopsy specimens: a prospective study of 814 thyroid FNAB patients.
Cañadas-Garre M; Becerra-Massare P; López de la Torre-Casares M; Villar-del Moral J; Céspedes-Mas S; Vílchez-Joya R; Muros-de Fuentes T; García-Calvente C; Piédrola-Maroto G; López-Nevot MA; Montes-Ramírez R; Llamas-Elvira JM
Ann Surg; 2012 May; 255(5):986-92. PubMed ID: 22504197
[TBL] [Abstract][Full Text] [Related]
36. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
[TBL] [Abstract][Full Text] [Related]
37. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
38. [Thyroid tumors--moleculargenetic causes and choices for target therapy].
Bela B; Sárka D; Vlasta S; Eliska V; Tereza H
Cas Lek Cesk; 2012; 151(3):123-7. PubMed ID: 22679698
[TBL] [Abstract][Full Text] [Related]
39. Expression of tpo mRNA in thyroid tumors: quantitative PCR analysis and correlation with alterations of ret, Braf , ras and pax8 genes.
Di Cristofaro J; Silvy M; Lanteaume A; Marcy M; Carayon P; De Micco C
Endocr Relat Cancer; 2006 Jun; 13(2):485-95. PubMed ID: 16728576
[TBL] [Abstract][Full Text] [Related]
40. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.
Zhu Z; Gandhi M; Nikiforova MN; Fischer AH; Nikiforov YE
Am J Clin Pathol; 2003 Jul; 120(1):71-7. PubMed ID: 12866375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
